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DNA methylationCervical carcinogenesis is driven by deregulated E6/E7 expression in dividing cells. A potential deregulating
mechanism is methylation of E2 binding sites in the viral long control region, thereby prohibiting HPVE2-
mediated transcription regulation. Here the frequency of HPV16E2BS methylation in cervical lesions (SCC,
n=29; CIN3, n=17) and scrapes (controls, n=17; CIN3, n=21) was investigated. Three E2BSs were ampli-
ﬁed using methylation independent PCR followed by speciﬁc detection of methylated CpGs using the Lumi-
nex® xMAP™ system. The frequency of E2BS1, E2BS3 and E2BS4 methylation was signiﬁcantly higher in SCC
compared to CIN3, i.e. 93% vs. 21% (pb0.01), 90% vs. 47% (pb0.01) and 69% vs. 5% (pb0.01), respectively and
ranged from 6 to 15% in controls. In scrapings of women with CIN3 methylation ranged from 24 to 33%.
In conclusion, we showed that the MIP–Luminex system is a highly sensitive method for methylation analy-
sis. HPV16 E2BSs methylation appeared highly frequent in SCC, with particularly E2BS3 methylation occur-
ring proportional to severity of cervical disease.
© 2011 Elsevier Inc. All rights reserved.Introduction
Infection with high-risk human papillomaviruses (hrHPVs) is a nec-
essary cause of cervical cancer. The major hrHPV type associated with
cervical cancer is HPV16, accounting for 50% of cervical cancers
(Jayshree et al., 2009; zurHausen, 2002). Viral replication and virion pro-
duction are coupled to the differentiation program of the infected squa-
mous epithelium and relies entirely on the host cell machinery (Chow
and Broker, 1994). Upon differentiation viral transcription, including
that of the viral oncogenes E6 and E7, increases and virus assembly oc-
curs in the squamous epithelia undergoing terminal differentiation.
Since differentiated cells have already lost the ability to divide, expres-
sion of E6 and E7 in differentiated layers does not result in cellular trans-
formation. However, increased expression of E6 and E7 in dividing cells
can cause oncogenic transformation, for which interaction of E6 and E7
with the tumor suppressor gene products p53 and pRb, respectively, is
essential (Boyer et al., 1996; Scheffner et al., 1990; Steenbergen et al.,
2005; zur Hausen, 2002).
Expression of E6 and E7 is regulated by the long control region
(LCR) to which cellular transcription factors like Activator Protein 1
(AP1) and speciﬁcity factor 1 (Sp1) can bind, as well as the viral pro-
tein E2 (Hoppe-Seyler and Butz, 1994). The LCR contains four E2 bind-
ing sites (E2BSs) characterized by the speciﬁc sequence 5′-nbergen).
rights reserved.ACCN6GGT-3′ (Fig. 1) (Androphy et al., 1987). Binding of E2 to the
proximal E2BSs hampers binding of host cell transcription factors to
adjacent DNA sequences, such as the TFIID and Sp1 binding sites over-
lapping E2BS3 and E2BS4, and thereby represses transcription initia-
tion (Tan et al., 1994). Vice versa, displacement of E2 at either one or
both E2BSs results in binding of TFIID to the TATA box or Sp1 to the
Sp1 binding site leading to transcription activation (Gloss and
Bernard, 1990; Tan et al., 1994). On the other hand, binding of E2 to
E2BS1 increases viral early gene expression (Dong et al., 1994;
Hegde, 2002; Steger and Corbach, 1997), resulting from a stimulation
of the function of the transcription factor YY1 binding the YY1-binding
site upstreamof E2BS1 (Tan et al., 2003), which at this site functions as
an activator (O'Connor et al., 1996). The interaction of E2 with E2BS1
is found to be the most stable interaction compared to binding of E2
to the other binding sites, with E2BS2 being the least stable (Sanders
and Maitland, 1994). When E2 concentrations are low, E2 binds pref-
erably to E2BS1, leading to E6/E7 expression. As the E2 concentrations
increase, the other E2 binding sites will also be bound by E2, resulting
in E6/E7 repression (Hegde, 2002). Hence, the observed change in E2
expression during cervical carcinogenesis, with E2 expression being
high in low grade cervical intraepithelial neoplasias (CIN1) and de-
creased in high grade CIN and carcinoma in situ (Bellanger et al.,
2011; Maitland et al., 1998; Xue et al., 2010), may at least in part ex-
plain the increased E6/E7 expression in high grade lesions.
Accordingly, it has been suggested that deregulated expression of
E6/E7 in dividing cells, which is believed to initiate the transforma-
tion process may, amongst others, result from loss of E2 repression.
Fig. 1. Schematic representation of the HPV16 LCR. Binding sites of transcription factors (speciﬁcity factor 1 (Sp1), Ying Yang 1 (YY1), Transcription Factor I (TFI), Nuclear Factor
(NFI), Activator Protein 1 (AP1), Transcription Factor IID (TFIID); boxes and circles) are shown. The LCR contains four E2BSs, with CpG dinucleotides located at nts 7455, 7461
(E2BS1; ACCGAATTCGGT), 7862 (E2BS2; ACCGTTTTGGGT), 37, 43 (E2BS3; ACCGAAATCGGT), 52 and 58 (E2BS4; ACCGAAACCGGT).
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of cervical cancer cells associated with reduced E6/E7 expression
upon E2 overexpression (Dowhanick et al., 1995; Wells et al., 2000).
A widely established mode of E2 downregulation is by viral DNA inte-
gration into the host cell DNA (Jeon and Lambert, 1995). When inte-
grated, the HPV genome is often disrupted within or just upstream of
the E2 open reading frame, thereby either affecting the continuity of
that gene or uncoupling it from its promoter sequence (zur Hausen,
2002). However, not all cervical lesions associated with a transform-
ing infection harbor integrated DNA. Recently, it has been reported
that only 19% of HPV16 positive CIN3 lesions and 55% of HPV16 pos-
itive cervical carcinomas contain integrated viral DNA (Vinokurova et
al., 2008). Moreover, previous studies often showed presence of an
intact E2 open reading frame in cervical cancers, despite absence of
E6/E7 repression (Bhattacharjee and Sengupta, 2006b; Cullen et al.,
1991).
This implies that other mechanisms are responsible for the deregu-
lation of E6/E7 in at least part of the cervical precancers and cancers.
One such a mechanism may involve DNA methylation, which is a
well-known and critical regulator of transcription (Bird, 2002). Each
E2BS contains one or two CpGdinucleotides,which are potential targets
for DNA methylation. In vitro studies have shown that methylation of
the CpG dinucleotides in the E2BS consensus sequence inhibits binding
of E2 (Thain et al., 1996), and that when E2BSs are methylated E2-
mediated transcription regulation is inhibited (Kim et al., 2003). More-
over, the inhibition of E2 binding upon E2BSmethylation also affects E1
binding to the origin of viral replication, as its afﬁnity is drastically de-
creased in the absence of E2 (Dixon et al., 2000; Frattini and Laimins,
1994; Lu et al., 1993; Sun et al., 1996). This implies that E2BS methyla-
tion decreases viral replication, thereby contributing to the switch from
a productive to a transforming infection.
Several studies have demonstrated that the HPV genome becomes
subject to DNA methylation during cervical carcinogenesis, though
present data on site speciﬁc methylation are inconclusive. Whereas
in some studies the LCR and E6 sequences of HPV16 were commonly
found to be unmethylated independent of the stage of neoplastic pro-
gression, the L1 region was densely methylated in cancers (Badal
et al., 2003; Fernandez et al., 2009; Sun et al., 2011). However, in
other studies, methylation of the LCR was frequently observed in pri-
mary cervical carcinomas, especially at the E2BSs (Bhattacharjee and
Sengupta, 2006a; Brandsma et al., 2009).
Most studies in which the methylation status of HPV16 was exam-
ined made use of methylation-dependent enzyme cleavage or bisul-
ﬁte sequencing (Badal et al., 2003; Bhattacharjee and Sengupta,
2006a; Ding et al., 2009; Fernandez et al., 2009; Hublarova et al.,
2009; Kim et al., 2003). However, the sensitivity of these techniques
may be insufﬁcient to detect low-abundance methylated DNA.
Microsphere-based suspension array technologies, such as the Lumi-
nex® xMAP™ system, offer a new platform for high-throughput de-
tection of DNA methylation. The Luminex system includes
polystyrene microspheres that are internally labeled with two dis-
tinct ﬂuorochromes, which can be mixed in various proportions
yielding about 100 distinguishable beads (Dunbar, 2006). In the
past, bead-based assays have been used predominantly forquantitative measurements of multiplexed protein–ligand interac-
tions or high-throughput nucleic acid detection through DNA hybrid-
ization (Eriksson et al., 2009; Nazarenko et al., 2008).
Here we describe the development of an E2BS methylation detec-
tion method based on the Luminex® xMAP™ system. With this meth-
od we determined the frequency of HPV16 E2BS methylation in
HPV16 positive CIN3 lesions, cervical cancers and scrapes of women
with CIN3 compared to HPV16 positive normal cervical samples.
Results
Development of a bead-based detection assay for the analysis of DNA
methylation at the E2BSs of HPV16
To determine the methylation status of the E2BSs of HPV16 we de-
veloped methylation-independent PCRs (MIPs) followed by a bead-
based detection assay using the Luminex® xMAP™ system, as is out-
lined in Fig. 2. In short, DNAs were ﬁrst treated with sodium bisulﬁte,
which converts unmethylated cytosines to uracils while leaving
methylated cytosines unaffected. This was followed by a MIP ampliﬁ-
cation with a pair of primers of which one was biotinylated at its 5′-
terminus. The ampliﬁed products were denatured and hybridized to
probes coupled to microspheres, which are either completely com-
plementary to the methylated CpGs (M-probes) or unmethylated
CpGs (U-probes). Next, streptavidin–phycoerythrin (SAPE) conju-
gates were added to bind the hybridized PCR products via streptavi-
din–biotin binding. Finally, the methylation status was determined
based on the ﬂuorescence signal of phycoerythrin (PE) coupled to
each microsphere-speciﬁc dye.
For ampliﬁcation of the E2BSs two primer sets were designed, one
for E2BS1, and one for E2BS3 and E2BS4 together (see Table 1). Since
pilot experiments revealed that the Luminex® xMAP™ system needs
at least two nucleotide differences to reliably discriminate between
the methylated and unmethylated status (data not shown) and E2BS2
contains only one CpG (ACCGTTTTGGGT), E2BS2 was excluded from
analysis. The two MIPs (E2BS1 and E2BS3-4) were validated on DNAs
isolated from HPV-negative primary foreskin keratinocytes (EKs) and
the HPV16 positive cervical cancer cell lines CaSki and SiHa. MIP prod-
ucts were formed for CaSki and SiHa, while no product was seen using
EKs (Fig. 3A). Upon sequencing analysis all three binding sites were
found to be methylated in CaSki cells, while no methylation was
detected in SiHa cells (Fig. 3B). The difference in methylation between
these two cell lines most likely relates to the number of copies present,
since CaSki cells contain approximately 400–600 copies ofHPV16,while
SiHa cells only contain 1–2 copies (Fernandez et al., 2009; Schwarz et
al., 1985; Yee et al., 1985). Van Tine et al. (2004) reported that only
one or a few of the HPV16 copies in CaSki cells showed active transcrip-
tion, whereas the remaining copies are silenced bymethylation. Due to
the extreme overrepresentation of methylated HPV16 DNA in CaSki
cells, the few copies of unmethylated viral DNA remained undetectable
upon bisulﬁte sequencing analysis.
To accurately determine the analytical sensitivity of the MIP–
Luminex detection system we used cloned MIP products of CaSki
and SiHa, the sequences of which were conﬁrmed by sequencing
Fig. 2. Principle of detecting methylation with the Luminex® xMAP™ system. Genomic DNA is treated with sodium bisulﬁte converting unmethylated cytosines into uracils,
while leaving methylated cytosines unaffected. Using MIP, PCR products are generated reﬂecting the same degree of methylation as present in the template ( : methylated CpG;
: unmethylated CpG). One of the primers is biotinylated (◊) at the 5′-terminus. Microspheres are coupled to probes speciﬁc for fully unmethylated (U-probe) or fully methylated
(M-probe) E2BS. Multiplexed hybridization reactions are performed, followed by incubation with SAPE to capture labeled PCR products via streptavidin–biotin binding. The meth-
ylation status is determined based on the ﬂuorescence signal of PE (PCR-product) coupled to each microsphere-speciﬁc dye (probe).
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Table 1
Primer and probe sequences. For luminex the reverse primers were tagged with biotin at their 5′-end.
MIP/Luminex





E2BS3-4 ATAATTTATGTATAAAATTAAGGG TACAACTCTATACATAACTAT 156
ACTB TGGTGATGGAGGAGGTTTAGTAAGT AACCAATAAAACCTACTCCTCCCTTAA 133
Probes
BS1 M TAATCGAATTCGGTTGTATGT 45
BS1 U TAATTGAATTTGGTTGTATGTTT 44
BS3 M CGTAATCGAAATCGGTTGAA 24
BS3 U GGTGTAATTGAAATTGGTTGA 23
BS4 M GAATCGAAATCGGTTAGTATA 89
BS4 U TTGAATTGAAATTGGTTAGTATA 49
a The forward primer for the BS1 region contains a CpG dinucleotide, therefore two primers were designed for this region, one containing a CG in its sequence, while the other
contains a TG.
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tion of E2BS methylation in further experiments.
Using these cloned MIP products all probes, i.e. an M-probe and an
U-probe for E2BS1, E2BS3, and E2BS4, were found to be highly speciﬁc
and to accurately discriminate between methylated and unmethylated
DNA (Table 2). High median ﬂuorescence intensities (MFI) were ob-
served with all three methylation positive M-probes using CaSki de-
rived MIP products, whereas MFIs for the unmethylated U-probe were
negligible. The opposite was seen for SiHa-derived MIP products.
To determine the limit of detection (LOD) of the MIP–Luminex
system, CaSki miniprep DNA was spiked with SiHa miniprep DNA in
order to obtain a dilution series of 2.5·106 copies (100%) to 0 copiesFig. 3. Methylation status of E2BSs in SiHa and CaSki. (A) PCR products for E2BS1 and
E2BS3-4 were formed in CaSki and SiHa. HPV negative primary keratinocytes (EK)
showed no E2BS1 and BS3-4 PCR product. The ACTB gene was included as a control
for bisulﬁte treatment. (B) Bisulﬁte sequencing revealed methylation in CaSki, but no
methylation in SiHa at all CpGs of all three E2BSs; CpG/TpGs of each E2BS are circled
in red.(0%) of methylated E2BSs in unmethylated background DNA and an-
alyzed in triplicate. The LODs were deﬁned as a MFI above the mean
background MFI (0%) plus three times the standard deviation. For
E2BS1 and E2BS3 the LOD was 0.5% (1.25·104 copies), and for
E2BS4 this was 1% (2.50·104 copies) (Fig. 4). Bisulﬁte sequencing
analysis of the same dilution series revealed a LOD for detecting
methylated DNA of 10% (data not shown), which is in line with previ-
ous reports (Myohanen et al., 1994). This indicates that the MIP–
Luminex system has at least a 10 times higher sensitivity for the de-
tection of methylated DNA compared to bisulﬁte sequencing.
Methylation of BS1, BS3 and BS4 in cervical tissue specimens and scrapings
Using the MIP–Luminex system, methylation of the E2BSs was ex-
amined in 19 CIN3 lesions and 29 cervical SCCs containing HPV16.
Seventeen scrapings of HPV16 positive women with normal cytology
without evidence of cervical (pre)malignant disease up to the next
screening round after 5 years served as disease negative controls, as
HPV16 positive normal cervical biopsies were insufﬁciently available.
For E2BS1, methylation positivity rates of 21% in CIN3 and 93% in SCC
were found. For E2BS3 methylation rates were 47% in CIN3 and 90% in
SCC and for E2BS4, these percentages were 5% and 69%, respectively.
The E2BS methylation frequencies for E2BS1, E2BS3 and E2BS4 in
scrapings with normal cytology were 12%, 6% and 18%, respectively
(Fig. 5A). The methylation frequencies for E2BS1, E2BS3 and E2BS4
were signiﬁcantly higher in cervical SCC specimens, both when com-
pared to controls (pb0.01) and CIN3 (pb0.01). Only for E2BS3 the
methylation frequency was found to be signiﬁcantly higher in CIN3
compared to controls (pb0.01). When combining the methylation re-
sults of the three binding sites, all (100%) SCC showed methylation of
at least one E2BS, compared to 58% of CIN3 lesions (pb0.01) and 24%
of controls (pb0.01). Additionally, the methylation levels of E2BS1,
E2BS3 and E2BS4 were signiﬁcantly higher in SCC compared to CIN3
and normal scrapings (pb0.01) (Figs. 5C–E). Only for E2BS3 the
methylation levels were signiﬁcantly higher in CIN3 compared to nor-
mal scrapings (pb0.01).
Next we determined whether E2BS methylation could also be
detected in cervical scrapings of women with underlying CIN3. ForTable 2
Summary of the obtained MFI values from the minipreps.
Sample SQ E2BS1U E2BS1M E2BS3U E2BS3M E2BS4U E2BS4M
MIP–Luminex results
CaSki M 18 2018 45 5699 25 3656
SiHa U 1617 7 3669 21 3026 19
Blank – 9 6 7 5 9 10
Fig. 4. Limit of detection of the MIP–Luminex system. Results of methylated E2BS1,
E2BS3 and E2BS4 using serially diluted CaSki miniprep DNA in a background of SiHa
miniprep DNA. For E2BS1 and E2BS3 as low as 0.5% methylated DNA and for E2BS4
as low as 1% methylated DNA can be detected.
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CIN3 were tested for E2BS methylation (Fig. 5B). MIP–Luminex anal-
ysis for E2BS1, E2BS3 and E2BS4 methylation showed methylation
positivity of 33%, 29% and 24%, respectively. When combining the re-
sults, 48% of scrapings were found to be methylation positive for at
least one E2BS, which is comparable to any methylation as detected
in CIN3 biopsies, i.e. 58%. This ﬁnding also implies that the use of nor-
mal cytology samples as controls for both tissue specimens and scrap-
ings is unlikely to have a major impact on the results obtained. For
E2BS3 and E2BS4 signiﬁcant differences in methylation levels be-
tween normal and CIN3 scrapings were found (pb0.05), which was
not seen for E2BS1 (Figs. 5C–E).
Conﬁrmation of MIP–Luminex results by bisulﬁte sequencing
To conﬁrm the results acquired with the MIP–Luminex, ﬁve CIN3
and six SCC tissue specimens were selected for further bisulﬁte se-
quencing analysis (Fig. 6). The results of bisulﬁte sequencing of the
cervical tissue specimens were identical to MIP–Luminex results for
E2BS1 and E2BS4. In all except two of the CIN3 specimens, E2BS3
methylation revealed identical results by MIP–Luminex analysis and
bisulﬁte sequencing. The two exceptions were methylation positive
by MIP–Luminex analysis but negative by bisulﬁte sequencing, most
likely reﬂecting the differences in LOD between the two techniques.
The MIP–Luminex positive, but sequencing negative CIN3 specimens
had M values of 38 and 78 MFI (methylation fraction (MF): 2% and
7%), whereas the SCC, which were positive using both techniques,
varied from 1111 to 4601 MFI (MF: 48–76%). This indicates that
these CIN3 tissue specimens could easily be missed using bisulﬁte
sequencing.Discussion
Analysis of DNA methylation at three E2BS of HPV16 using the
newly developed MIP–Luminex system in cervical tissue biopsies
revealed an increase in methylation at E2BS1 and E2BS3 with severity
of cervical disease, i.e. 21% and 47% in CIN3 lesions and 93% and 90% in
SCC, respectively. The methylation frequency of E2BS3 was signiﬁ-
cantly lower in normal cytology controls, in which 6% of samples test-
ed positive. Methylation at E2BS4 was low in both normal cytology
controls and CIN3 (5–18%), but increased in SCC (69%). When scoring
for methylation at any E2BS, 100% of SCCs and 58% of CIN3 lesions
were found to be positive, compared to 24% of controls.
The methylation frequencies detected in this study are higher
compared to those reported in previous studies using bisulﬁte se-
quencing or pyrosequencing (Fernandez et al., 2009; Sun et al.,
2011). These observations as well as the discrepancies between pub-
lished data on HPV DNAmethylation may at least in part be related to
differences in techniques used. As suggested by Sun et al. (2011),
methylated molecules might be overrepresented when using bisulﬁte
treatment followed by cloning and sequencing. In this case the actual
methylation pattern might not be correctly reﬂected, since only a lim-
ited number of clones are sequenced. In other studies methylation-
sensitive enzyme restriction cleavage was used (Badal et al., 2003;
Bhattacharjee and Sengupta, 2006a), which is prone to false positives,
due to incomplete digestion or false negatives, due to low abundance
DNA methylation (van Vlodrop et al., 2011). With the use of MIP, as
applied in the current study, the PCR products analyzed reﬂect the
same degree of methylation as present in the template. Moreover,
the speciﬁc detection of methylated and unmethylated CpGs by the
Luminex® xMAP™ system appeared to be highly speciﬁc and sensi-
tive, with a limit of detection of 0.5–1% for E2BS1/E2BS3 and E2BS4,
respectively (Fig. 4).
Present ﬁndings, showing methylation of all three investigated
HPV16 E2BS in CaSki cells and complete absence of methylation in
SiHa cells, is in concordance with previous reports (Fernandez et al.,
2009; Kalantari et al., 2004; Kalantari et al., 2008; Rajeevan et al.,
2006; Sun et al., 2011), and most likely relates to the difference in
viral copy numbers between the two cell lines. Methylation of the
400–600 copies in CaSki cells ensures tight expression regulation of
E6 and E7 (Fernandez et al., 2009; Kalantari et al., 2008; Van Tine et
al., 2004). In these cells it was shown that active viral RNA transcrip-
tion occurs only at a single-copy or low copy-number site on a deriv-
ative of chromosome 14, whereas all other loci were inactive.
Transcription from the silent (i.e. methylated) viral DNA copies was
activated upon growth in the presence of a DNAmethylation inhibitor
in a subset of cells (Van Tine et al., 2004), suggestive of additional
mechanisms regulating gene silencing. In contrast in SiHa cells, con-
taining only 1–2 copies of HPV16 per cell, viral DNA is found to be in-
tegrated within the host cell DNA by interruption of its E2 gene
(Baker et al., 1987). Hence interference with E2 binding by E2BS
methylation is redundant in SiHa cells. From this it may be inferred
that also in cervical high grade lesions and carcinomas which often
harbor multiple viral copies (Gravitt et al., 2007; Snijders et al.,
2006; Wu et al., 2006), viral transcripts are originating from a single
or a few copies only and the remaining copies being silenced by
methylation.
In the clinical specimens tested in this study, E2BS1 and E2BS3
revealed the highest methylation rate compared to E2BS4. A recent
study by Vinokurova et al. has demonstrated that methylation of
E2BS1 results in an increased activity of the p97 promoter in the pres-
ence of E2, which intriguingly was associated with binding of a yet
uncharacterized protein complex (Vinokurova and von Knebel
Doeberitz, 2011). In close proximity to E2BS3, the second most fre-
quently methylated E2BS in SCC, resides a Sp1 binding site and the
TATA box (Fig. 1). Whereas in the absence of methylation E2 com-
petes with the transcription factors Sp1 and TFIID for binding to the
Fig. 5. Summary of E2BS MIP–Luminex results in cervical tissue specimens and scrapings. DNA methylation is depicted in black; white boxes indicate unmethylated DNA. (A) The
upper section represents cytomorphologically normal scrapings of HPV16 positive women without CIN lesions during 5-year follow-up. The two lower sections represent cervical
tissue specimens of HPV16 positive women with CIN3 or SCC. (B) This section represents scrapings classiﬁed as moderate dyskaryosis or worse of HPV16 positive women who de-
veloped CIN3 within 18 months of follow-up. (C-E) Association between E2BS methylation, disease stage, and sample type. Scatter plots of the levels of E2BS1 (C), E2BS3 (D), and
E2BS4 (E) methylation. On the y-axes levels of methylated E2BS are presented; on the x-axes the samples are grouped for each disease stage and sample type. The grey dotted line
indicates the cut off value.
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binding by E2BS methylation (Thain et al., 1996) induces TFIID and
Sp1-mediated transcription activation. Earlier studies have shown
that methylation of CpG dinucleotides has little or no effect on the
binding of the transcription factors Sp1 (near E2BS3) and YY1 (near
E2BS1) (Gaston and Fried, 1995; Holler et al., 1988). However, we
cannot rule out the possibility that binding of these transcription
sites might be blocked indirectly, either by conformational changes
or by interacting with methyl-CpG-binding proteins (Boyes and
Bird, 1992; Tazi and Bird, 1990). Taken together, current data indicate
that methylation of E2BS1 as well as E2BS3 and E2BS4 results in an in-
creased expression of E6/E7.
In this study, the methylation status of E2BS2 was not examined,
due to technical limitations. Previous work done by Kim et al.(2003) reported the highest methylation rate of E2BS2 compared to
the other three E2BSs in a cervical epithelial cell line that was isolated
from an HPV16-infected patient. In contrast, in a study on clinical
specimens the CpG residue in E2BS2 appeared unmethylated in near-
ly all CIN and cervical cancer specimens (Piyathilake et al., 2010). Al-
though we were unable to study methylation at E2BS2 using the
presently used system, this might be accomplished by the incorpora-
tion of a locked nucleic acid (LNA) at the CpG site in the probe se-
quence. Incorporation of LNAs in oligonucleotides has been shown
to improve nucleotide discrimination (Vester and Wengel, 2004).
Previous studies have proposed that testing for HPV DNA methyl-
ation may serve as a disease marker for progressive cervical disease
(Badal et al., 2003; Ding et al., 2009; Hublarova et al., 2009; Sun et
al., 2011). Present ﬁndings indicate that also the speciﬁc detection
Fig. 6. For comparison, the MIP–Luminex (LU) and bisulﬁte sequencing (SQ) results are
presented for E2BS methylation in CaSki, SiHa, CIN3 and SCC specimens. Black boxes in-
dicate the sample was methylated and white boxes indicate the sample was
unmethylated.
363S. Snellenberg et al. / Virology 422 (2012) 357–365of E2BS methylation may be of diagnostic value. Although all SCC
showed E2BS methylation at any E2BS, only a subset of CIN3 lesions
was methylation positive. Hence, E2BS methylation analysis may
serve as a complementary marker to host methylation markers,
such as CADM1 and MAL (Overmeer et al., 2008; Overmeer et al.,
2009; Overmeer et al., 2010), to improve the early detection of high
grade cervical disease. In this respect, E2BS3 methylation seems to
be the most promising marker, since only 6% of the normal samples
were methylated compared to 47% of CIN3 biopsies.
In this study we showed that the MIP–Luminex system is a highly
sensitive and reliable method for the detection of HPV16 E2BS meth-
ylation. Hence, this system may in the future be extended further by
inclusion of other CpG sites within the HPV-methylome, such as
methylation within the L1 region which appears highly predictive
for high-grade disease (Sun et al., 2011).
In conclusion, we showed that the MIP–Luminex system is a high-
ly sensitive and reliable method for the detection of methylation at
E2BSs. Methylation of HPV16 E2BSs appeared highly frequent in
SCCs, indicating that it is a rather late event in cervical carcinogenesis.
Particularly methylation of E2BS3 which is most frequent in CIN3 le-




Primary human foreskin keratinocytes (EKs) and the cervical can-
cer cell lines CaSki and SiHa were cultured as described previously
(Steenbergen et al., 2004).
Cervical samples
This study followed the ethical guidelines of the Institutional Re-
view Board of the VU University Medical Center. Formalin-ﬁxed,
parafﬁn-embedded (FFPE) samples were collected from patients
with CIN3 (n=19) and cervical SCC (n=29), which were HPV16
positive as determined by the method described below. The mean
age of all women included in this study was 43 years (range 26–74).
Per histological group the women had the following mean ages:
37 years (range 26–74) in the CIN3 group and 42 years (range
30–74) in the SCC group. All specimens were collected during the
course of routine clinical practice of women who underwent biopsy
or surgery and were stored within the tissue bank of the Department
of Pathology at the VU University Medical Center. A series of sevenconsecutive tissue sections were cut from each specimen. The ﬁrst
and last sections (4 μm) were stained with hematoxylin and eosin
for histological diagnosis by an expert pathologist. Five in between
sections (10 μm) were used for DNA isolation and methylation
analysis.
Cervical scrapings were obtained from the population-based cer-
vical screening trial POBASCAM (Bulkmans et al., 2007). We included
17 cervical scrapings of HPV16 positive women with normal cytology
without evidence of CIN disease up to the next screening round (after
5 years) and 21 abnormal scrapings of HPV16 positive women with
CIN3. The median age of HPV16 positive women with normal cytolo-
gy was 34 years (range 18–46), and that of the womenwith abnormal
cytology was 35 years (range 24–56).
DNA extraction, HPV typing and bisulﬁte modiﬁcation
FFPE tissue sections, cervical scrapings and cell cultures were in-
cubated in proteinase K solution (0.1 mg/ml) for 48 h at 56 °C at
600 rpm. DNA was isolated using the High Pure PCR Template Prepa-
ration kit (Roche Diagnostics, Almere, The Netherlands) according to
the manufacturer's recommendations. Genomic DNA from cell cul-
tures was isolated with UltraPure™ Phenol:Chloroform:Isoamyl Alco-
hol (Invitrogen, Breda, The Netherlands).
HPV detection and genotyping was performed using the GP5+/
6+−PCR with an enzyme immunoassay (EIA) readout followed by
reverse-line-blot analysis of EIA positive cases (Snijders et al., 2005).
For E2BS analysis DNAs were subjected to bisulﬁte treatment with
the EZ DNA Methylation Kit™ (Zymo Research, Orange, CA, USA)
according to the manufacturer's recommendations.
Methylation-Independent-Speciﬁc PCR (MIP)
Primers used forMIP of E2BS1 andE2BS3-4 are listed in Table 1. In the
PCR reaction, 50 ng of bisulﬁte treated genomic DNAwas ampliﬁedwith
FastStart Taq PCR buffer (Roche Diagnostics) supplemented with 2 mM
MgCl2, 500 nM of each primer, each dNTP at 200 μM, and 0.75 U of Fast-
Start Taq DNA polymerase in a total volume of 30 μl. Ampliﬁcation reac-
tion was carried out in a GeneAmp® PCR system 9800 (Applied
Biosystems, Nieuwerkerk a/d IJssel, TheNetherlands) using the following
conditions: 96 °C for 5 min, followed by 45 cycles of 95 °C for 30 s, 45 °C
or 50 °C, for BS1 or BS3-4, respectively, for 30 s and 72 °C for 45 s, with a
ﬁnal extension of 72 °C for 4 min. MIP products were analyzed by elec-
trophoresis on 2% agarose gels.
Cloning of PCR products
MIP-products of SiHa and CaSki were cloned into pCR®-Blunt II-
TOPO vector (Invitrogen, Breda, The Netherlands). Multiple colonies
of each construct were grown in selection medium at 37 °C overnight
and plasmids were isolated with GeneJETTM Plasmid Miniprep Kit
(Fermentas, St. Leon-Rot, Germany) according to the manufacturer's
recommendations. The insert of eachminiprepwas veriﬁed by sequenc-
ing analysis.
Bisulﬁte sequencing
To remove unincorporated primers and dNTPs, 2 μl ExoSAP-IT re-
agent (1:1; USB, HighWycombe, United Kingdom) was added to each
MIP product. The mixture was incubated at 37 °C for 15 min, followed
by 15 min at 80 °C to inactivate the enzymes. Samples were se-
quenced using the BigDye Terminator v3.1 Cycle Sequencing Kit on
an ABI Prism 3130-Avant Genetic Analyzer (Applied Biosystems)
according to manufacturer's recommendations. After 30 cycles of am-
pliﬁcation, excess dye terminator was removed with the BigDye XTer-
minator® Puriﬁcation Kit (Applied Biosystems). Sequences were
364 S. Snellenberg et al. / Virology 422 (2012) 357–365analyzed using Chromas Lite (http://www.technelysium.com.au/
chromas_lite.html).
Labeling of microspheres with probes
Two probes were designed for each E2BS for Luminex detection
(Table 1). Carboxylated microspheres (2.5·106; Biorad, Veenendaal,
The Netherlands) were pelleted in a microcentrifuge for 2 min at
13,000 rpm and supernatant was carefully removed. The micro-
spheres were dissolved in 25 μl MES buffer (0.1 M, pH 4.5; Sigma-
Aldrich, Zwijndrecht, The Netherlands), 4 μl of amino-substituted
capture probe (100 μM) and 2 μl of a freshly made solution of
100 mg/ml 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydro-
chloride (EDAC) (Pierce Thermo Scientiﬁc, Rockford, IL, USA). The
mixture of microspheres, capture probes and EDAC was vortexed
brieﬂy and incubated at room temperature for 30 min at 300 rpm in
the dark. After 15 min the reaction was mixed by brief vortexing. A
second incubation step was done adding 2 μl EDAC (100 mg/ml).
After the coupling reaction, 500 μl of 0.02% Tween 20 (Sigma-Aldrich)
was added to the microspheres, followed by centrifugation for 2 min
at 13,000 rpm. The supernatant was carefully removed and the
coupled microspheres were washed in 500 μl of 0.1% SDS (Sigma-Al-
drich) by vortex and centrifuged for 2 min at 13,000 rpm. Finally, the
supernatant was removed and the capture-probe conjugated micro-
spheres were resuspended in 100 μl of TE-buffer (10 mM TrisHCl,
1 mM EDTA, pH8) and stored at 4 °C in dark.
Hybridization protocol
To 10 μl of biotinylated DNA target (MIP product), 0.33 μl of conju-
gated microspheres, 33 μl hybridization buffer (0.15 M TMAC, 75 mM
TrisHCl, 6 mM EDTA, 1.5 g/l Sarkosyl, pH8) and 7 μl TE-buffer were
added. Hybridization reactions were carried out with an initial step
of 95 °C for 3 min, followed by 30 min at 45 °C with shaking speed
of 500 rpm. Each sample was transferred into ﬁlterplates (multi-
screen HTS; Millipore, Bedford, MA, USA) containing 200 μl blocking
buffer (0.02% Tween 20). Vacuum ﬁltration was performed for sample
collection, followed by an additional washing step with blocking buff-
er. To each sample 75 μl SAPE (Moss, 1:600) was added and incubated
for 15 min at 45 °C with a shaking speed of 500 rpm. Samples were
washed three times with blocking buffer and resuspended in 100 μl
of blocking buffer. For each experiment, 100 events of each subset
of microspheres were analyzed on the Luminex® xMAP™ system
(xMAP technology, Austin, TX) to obtain a median ﬂuorescence inten-
sity value (MFI) that was representative of the whole population of
each set of beads. TheM ﬂuorescence signal intensity from hybridiza-
tion with the M-probe and the U signal intensity from hybridization
with the U-probe were used to calculate the methylation fraction
(MF) with the following formula:
MF %ð Þ ¼ M
M þ U ⋅100%
The 99% conﬁdence interval of the 17 scrapings with normal cytol-
ogy was used as cut-off value to calculate the percentage of
methylation-positive samples.
Statistical analysis
Statistical analysis was performed using SPSS (version 14.0).
Associations between methylation frequencies and levels versus
histotypeswere analyzed using a χ2-test andMann–Whitney U-test, re-
spectively. A two-sided p-value of b0.05 was considered statistically
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